For , re~t4l11ve <Be only. MJ'. til be h wfth pllyskJilIJs.

Doctor, I know that you have been anxious to have a new product in your treatment arsenal. Today, I am excited to share with you new IQUIX® (Ievofloxacin ophthalmic solution) 1.5%, a newer­generation fluoroquinolone that

delivers powerful sustained levels of concentration, both above and below the ocular surface. New IQUIX® 1.5% takes concentrat,ion to a new level.

®

I FORTRAIN G ,pu POSES ONLY. (Ievofloxacin aphtha mic or fOR DETAIUNG. DO NOT DUPLICATE OR DISTRIBUTE. so ut"on) 1.5%

Ta Concan tion a ew Ll::=iVe=

ApPII"ll)\led 0

High Btnined, Concentratio

R3p:aly ac 'a~13l;' ~llS1alns 111 /'1 concenlli ions i~ tears"

Penelrates human co.-neal Issue ood llq1.:eous 11U1nor to con:enlrations thai exceed MIG. valll~s of commo ocular pathogens'

High Concentr; • n and ODv 89

Broad c(werage of gram-l1l3g3tlve and gram-poo; i~e pathogens, Including P aerlJgillosB, S. marcescens. S. awe ,S, epiderm/dis, and S. pr.-elJm(lniae'

Qc;ular TRU.s . s~etll data documents h/g susceptibility of key (2QOO.2007}'

Dual mechanism of action $imilar 0 galifloxacin and moxifioxac nt

II-·Yoltel'l!l't:ad 'Co B.tion

Low cylotoXJly to bolh human comool do heiJal ce!ls and keratocyles'

Pw.~ervative--free. near neutral pH form~iatlo~l

..........- .......,..--­,.,

FORTiRAJNI G PURPOSES 0 LV: OT FOR DETAtlING. DO, 0 DUPLICATE OR D STRIBU

oII • 1l.C.. II~ t~lIar'a ':'~ I)s:cro .s';mhQ Co lid, Tokyc. J,mol1 ..,. _. Urllltnil«:l Lv $.:I Ov~ 1.:trrlpeJe. t '11. nj §mtlll1·

(I..'Lio1J1ttTl,;:::! t·yVrST/ooJ(.{JN ~m-=f1uU :So LLC. J~k~onville. -/orjl'l" .2.­VISTAKO 14 OJ rttilW!:i!W lrad~ .. oIVI~rJ.\KOr-.: f'llarmacl!u\ cals, LLof

1/ S AKU'- r,·"'ar acllllicals, LLC 200i' Allllq "IS reserved 10107 2707)0-014

New IQUIX 1.5% is the only newer

fluoroquinolone approved for treatment

of corneal ulcers, and deli,vers high

sustained concentrations where your

patients may need it most. It provides

rapid penetration in tears that is sustained over time. IQUIX® also achieves

high concentrations in human corneal

tissue and aqueous humor that exceed

the MIC90 values of common ocullar pathogens. IQUIXc:; has broad coverage of

gram-negative pathogens, including

Pseudomonas aeruginosa and Serratia

marcescens, as well as gram-positive

pathogens, including Staph epidermidis.

The high susceptibility of key ocular

pathogens is further documented by the

Ocular TR.U.S.T surveillance data. But

equally important, IQUIX® is well

tolerated. It is preservative-free with a

near neutra I pH, and is less cytotoxic tha n

other newer FQs.

Pro e: Now that you know how new IQUIXill 1.5% measures up to the other new r fQ . at you use r., your practice, will you pr scri e IQUI XQI wnen you nBed a potent nuoroquinolon with sustained con centrations ov r ti m@?

®

(Ievofloxacin ophthalm"c SO utio ) .5%,

Doctor, you should feel confident that IQUIX® delivers sustained levels of

concentration above and below the

ocular surface.

Ta e -one nation 0 a Ne evel

In-fused with~sed with, R'E MOD U 1 I N~' . (treprostin11 50dium) Injectio

When initial therapy loses momentum, think REMODULlN@

'5t a nlv Prostacyclin for Bo nfusio

JLlNf/ll delivers the power of continuously infused prostacyclin with:

packs necessary a:::. half-life

rized pump options

)L1N delivers results

led hemodynamics

;hed symptoms associated with exercise in NYHA Class II-IV patients

ted deterioration In those requiring transition from Flolan®

JLlN has flexible dosing

to titrate to effect

t8 hours (IV) or 72 hours (SC) between reservoir changes

nt Safety Information: Chronic intravenous infusions of JLlN are delivered using an Indwelling central venous catheter. e is associated with the risk of blood stream infections (BSI) IS, which may be fatal.

Iportant Safety Information on page 17. II prescribing informiltio~ in pocket.

liled erapeutics

J •

•ODU (treprostinil sodium) Injection

Joanne

REMODULIN patient